Calcimedica Inc (CALC)

$3.00 -0.23 (-7.12%)
Market Cap 48.10M
Revenue (ttm) 0.00
Net Income (ttm) -13.70M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 7,800
Avg Vol 47,532
Day's Range N/A - N/A
Shares Out 14.40M
Stochastic %K 64%
Beta 1.37
Analysts Strong Sell
Price Target $17.00

Company Profile

CalciMedica, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for illnesses caused by inflammatory and immunologic processes and direct cellular damage. The company's lead product candidate comprises Auxora, an intravenous formulated small molecule calcium release-activated calcium (CRAC) channel inhibitors for the treatment of acute pancreatitis, asparaginase-induced pancreatic toxicity, and acute kidney injury, as well as severe COVID-19 pneumonia. It also d...

Industry: Biotechnology
Sector: Healthcare
Phone: 858 952 5500
Address:
505 Coast Boulevard South, Suite 307, La Jolla, United States
MrAlientrader
MrAlientrader Nov. 14 at 9:03 PM
$CALC down 7% with only 7k shares traded :)
0 · Reply
MrAlientrader
MrAlientrader Nov. 14 at 4:01 PM
$CALC seems no one is selling except thise price manipulator’s fake trading
0 · Reply
d_risk
d_risk Nov. 12 at 10:23 PM
$CALC - CalciMedica, Inc. - 10Q - Updated Risk Factors CALC’s 10-Q risk factors now focus on expanded clinical trial, regulatory, and commercialization hurdles for Auxora, new IP and trademark disputes, detailed compliance and international trade risks, stock volatility, and the impact of future share sales—while streamlining prior disclosures and removing some economic and delisting risks. #Pharmaceuticals #StockVolatility #IntellectualProperty #RegulatoryRisk #ClinicalTrials 🟢 Added 🟠 Removed https://d-risk.ai/CALC/10-Q/2025-11-12
0 · Reply
PresumingEd
PresumingEd Nov. 10 at 12:17 PM
$CALC https://uk.marketscreener.com/news/calcimedica-presents-data-from-preclinical-study-of-auxoraa-in-an-animal-model-of-aki-at-asn-kidne-ce7d5fd8d88dff26
0 · Reply
clueful
clueful Nov. 6 at 1:01 PM
$CALC once this flies and actually gets found by people, it can only go up. And a lot.
0 · Reply
MrAlientrader
MrAlientrader Nov. 5 at 9:02 PM
$CALC started accumulating again below $3, thank you shorts for another opportunity, please drive it lower
0 · Reply
AmySharp603
AmySharp603 Oct. 29 at 4:50 PM
$CALC creating smarter solutions; AITX creating safer streets — AI-powered RADCam Enterprise now helping Taylor Police deter crime in real time. 🚓
0 · Reply
Regzw
Regzw Oct. 27 at 8:37 PM
$BYND everybody check out $CALC most insider buying I ever saw!!!
3 · Reply
Regzw
Regzw Oct. 27 at 8:37 PM
$GME everybody check out $CALC most insider buying I ever saw!!!!
0 · Reply
Regzw
Regzw Oct. 27 at 8:35 PM
$BB everybody check out $CALC most insider buying I ever saw!!!!!
0 · Reply
Latest News on CALC
CalciMedica Reports Third Quarter 2025 Financial Results and Provides Clinical & Corporate Updates

Nov 12, 2025, 7:01 AM EST - 2 days ago

CalciMedica Reports Third Quarter 2025 Financial Results and Provides Clinical & Corporate Updates

CalciMedica Announces Publication in JCI Insight of Preclinical Data Supporting CRAC Channel Inhibitor as a Potential Therapy for Pulmonary Arterial Hypertension

Nov 12, 2025, 7:00 AM EST - 2 days ago

CalciMedica Announces Publication in JCI Insight of Preclinical Data Supporting CRAC Channel Inhibitor as a Potential Therapy for Pulmonary Arterial Hypertension

CalciMedica Presents Data from Preclinical Study of Auxora™ in an Animal Model of AKI at ASN Kidney Week 2025

Nov 10, 2025, 7:00 AM EST - 4 days ago

CalciMedica Presents Data from Preclinical Study of Auxora™ in an Animal Model of AKI at ASN Kidney Week 2025

CalciMedica and Telperian Announce Collaboration to Integrate Innovative Artificial Intelligence Engine to Analysis of Clinical Trials of Auxora™

Oct 14, 2025, 7:00 AM EDT - 4 weeks ago

CalciMedica and Telperian Announce Collaboration to Integrate Innovative Artificial Intelligence Engine to Analysis of Clinical Trials of Auxora™

CalciMedica to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

Sep 2, 2025, 7:00 AM EDT - 2 months ago

CalciMedica to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

CalciMedica Reports Second Quarter 2025 Financial Results and Provides Clinical & Corporate Updates

Aug 12, 2025, 7:00 AM EDT - 3 months ago

CalciMedica Reports Second Quarter 2025 Financial Results and Provides Clinical & Corporate Updates

CalciMedica to Participate in the H.C. Wainwright 4th Annual Kidney Virtual Conference

Jul 8, 2025, 7:00 AM EDT - 4 months ago

CalciMedica to Participate in the H.C. Wainwright 4th Annual Kidney Virtual Conference

CalciMedica Announces Publication in the American Journal of Nephrology Discussing Design and Rationale of Phase 2 KOURAGE Trial of Auxora™ in AKI with Respiratory Failure

Jun 25, 2025, 7:00 AM EDT - 5 months ago

CalciMedica Announces Publication in the American Journal of Nephrology Discussing Design and Rationale of Phase 2 KOURAGE Trial of Auxora™ in AKI with Respiratory Failure

CalciMedica Announces Upcoming Symposium at the 43rd Vicenza Course AKI-CRRT-EBPT and Critical Care Nephrology Meeting

Jun 12, 2025, 7:00 AM EDT - 5 months ago

CalciMedica Announces Upcoming Symposium at the 43rd Vicenza Course AKI-CRRT-EBPT and Critical Care Nephrology Meeting

CalciMedica Reports First Quarter 2025 Financial Results and Provides Clinical & Corporate Updates

May 14, 2025, 7:00 AM EDT - 6 months ago

CalciMedica Reports First Quarter 2025 Financial Results and Provides Clinical & Corporate Updates

CalciMedica Announces Presentations at Upcoming Medical Meetings

Apr 17, 2025, 7:00 AM EDT - 7 months ago

CalciMedica Announces Presentations at Upcoming Medical Meetings

CalciMedica to Participate in the Jones Healthcare and Technology Innovation Conference

Apr 1, 2025, 7:00 AM EDT - 8 months ago

CalciMedica to Participate in the Jones Healthcare and Technology Innovation Conference

CalciMedica Reports 2024 Financial Results and Provides Clinical & Corporate Updates

Mar 27, 2025, 7:00 AM EDT - 8 months ago

CalciMedica Reports 2024 Financial Results and Provides Clinical & Corporate Updates

CalciMedica Secures Credit Facility for Up to $32.5 Million

Mar 5, 2025, 7:00 AM EST - 9 months ago

CalciMedica Secures Credit Facility for Up to $32.5 Million

CalciMedica Presents AKI Data from a Post-Hoc Analysis of the Phase 2 CARDEA trial of Auxora™ in Severe COVID-19 Pneumonia at the 30th International AKI & CRRT Conference

Mar 4, 2025, 7:00 AM EST - 9 months ago

CalciMedica Presents AKI Data from a Post-Hoc Analysis of the Phase 2 CARDEA trial of Auxora™ in Severe COVID-19 Pneumonia at the 30th International AKI & CRRT Conference

CalciMedica Announces Upcoming Plenary Presentation at the 30th International AKI & CRRT Conference

Feb 19, 2025, 7:00 AM EST - 9 months ago

CalciMedica Announces Upcoming Plenary Presentation at the 30th International AKI & CRRT Conference

CalciMedica to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Feb 3, 2025, 4:05 PM EST - 10 months ago

CalciMedica to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference

CalciMedica Announces Appointment of Dr. Alan Glicklich to Board of Directors

Jan 14, 2025, 7:00 AM EST - 10 months ago

CalciMedica Announces Appointment of Dr. Alan Glicklich to Board of Directors

CalciMedica to Participate in the Piper Sandler 36th Annual Healthcare Conference

Nov 21, 2024, 8:00 AM EST - 1 year ago

CalciMedica to Participate in the Piper Sandler 36th Annual Healthcare Conference

CalciMedica Reports Third Quarter 2024 Financial Results and Provides Clinical & Corporate Updates

Nov 13, 2024, 7:00 AM EST - 1 year ago

CalciMedica Reports Third Quarter 2024 Financial Results and Provides Clinical & Corporate Updates

CalciMedica Strengthens Leadership Team with Appointment of Stephen Bardin as Chief Financial Officer

Nov 7, 2024, 7:00 AM EST - 1 year ago

CalciMedica Strengthens Leadership Team with Appointment of Stephen Bardin as Chief Financial Officer

CalciMedica Announces Pricing of Public Offering of Common Stock

Oct 30, 2024, 10:11 PM EDT - 1 year ago

CalciMedica Announces Pricing of Public Offering of Common Stock

CalciMedica Announces Proposed Public Offering of Common Stock

Oct 30, 2024, 4:50 PM EDT - 1 year ago

CalciMedica Announces Proposed Public Offering of Common Stock

CalciMedica to Present Late-Breaking Positive Data, Including a Win Ratio Analysis, from Phase 2b CARPO Trial of Auxora™ in Acute Pancreatitis (AP) at the American College of Gastroenterology (ACG) 2024 Annual Scientific Meeting

Oct 30, 2024, 7:00 AM EDT - 1 year ago

CalciMedica to Present Late-Breaking Positive Data, Including a Win Ratio Analysis, from Phase 2b CARPO Trial of Auxora™ in Acute Pancreatitis (AP) at the American College of Gastroenterology (ACG) 2024 Annual Scientific Meeting

CalciMedica to Host a Call to Review Full Data Set, including a Win Ratio Analysis, from Phase 2b CARPO Trial of Auxora™ in Acute Pancreatitis (AP)

Oct 28, 2024, 4:05 PM EDT - 1 year ago

CalciMedica to Host a Call to Review Full Data Set, including a Win Ratio Analysis, from Phase 2b CARPO Trial of Auxora™ in Acute Pancreatitis (AP)

CalciMedica Announces Upcoming Late-Breaker Plenary Presentation at the American College of Gastroenterology (ACG) 2024 Annual Scientific Meeting

Oct 16, 2024, 8:00 AM EDT - 1 year ago

CalciMedica Announces Upcoming Late-Breaker Plenary Presentation at the American College of Gastroenterology (ACG) 2024 Annual Scientific Meeting

CalciMedica to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Sep 3, 2024, 8:00 AM EDT - 1 year ago

CalciMedica to Present at the H.C. Wainwright 26th Annual Global Investment Conference

CalciMedica Reports Second Quarter 2024 Financial Results and Provides Clinical & Corporate Updates

Aug 12, 2024, 4:10 PM EDT - 1 year ago

CalciMedica Reports Second Quarter 2024 Financial Results and Provides Clinical & Corporate Updates

CalciMedica Announces First Patient Enrolled in Phase 2 KOURAGE Trial of Auxora™ in Severe Acute Kidney Injury (AKI)

Jul 9, 2024, 7:30 AM EDT - 1 year ago

CalciMedica Announces First Patient Enrolled in Phase 2 KOURAGE Trial of Auxora™ in Severe Acute Kidney Injury (AKI)

CalciMedica Announces Presentations at Two Upcoming Healthcare Investment Conferences

Jul 8, 2024, 8:00 AM EDT - 1 year ago

CalciMedica Announces Presentations at Two Upcoming Healthcare Investment Conferences

CalciMedica Set to Join Russell Microcap® Index

Jul 1, 2024, 8:00 AM EDT - 1 year ago

CalciMedica Set to Join Russell Microcap® Index

CalciMedica Announces Positive Topline Data from Phase 2b CARPO Trial of Auxora™ in Acute Pancreatitis (AP)

Jun 27, 2024, 8:00 AM EDT - 1 year ago

CalciMedica Announces Positive Topline Data from Phase 2b CARPO Trial of Auxora™ in Acute Pancreatitis (AP)

CalciMedica to Host Conference Call to Review Topline Data from Phase 2b CARPO Trial of Auxora™ in Acute Pancreatitis (AP)

Jun 26, 2024, 4:05 PM EDT - 1 year ago

CalciMedica to Host Conference Call to Review Topline Data from Phase 2b CARPO Trial of Auxora™ in Acute Pancreatitis (AP)

CalciMedica Reports First Quarter 2024 Financial Results and Provides Clinical & Corporate Updates

May 13, 2024, 4:05 PM EDT - 1 year ago

CalciMedica Reports First Quarter 2024 Financial Results and Provides Clinical & Corporate Updates

CalciMedica Announces Upcoming Presentation at Digestive Disease Week 2024

May 7, 2024, 8:00 AM EDT - 1 year ago

CalciMedica Announces Upcoming Presentation at Digestive Disease Week 2024

CalciMedica Announces Last Patient Enrolled in Phase 2b CARPO Trial of Auxora™ in Acute Pancreatitis

Apr 24, 2024, 8:00 AM EDT - 1 year ago

CalciMedica Announces Last Patient Enrolled in Phase 2b CARPO Trial of Auxora™ in Acute Pancreatitis

CalciMedica Reports 2023 Financial Results and Provides Clinical & Corporate Updates

Mar 28, 2024, 7:00 AM EDT - 1 year ago

CalciMedica Reports 2023 Financial Results and Provides Clinical & Corporate Updates

CalciMedica Presents Data from Preclinical Studies of Auxora in Acute Kidney Injury at the 29th International AKI & CRRT Conference

Mar 13, 2024, 8:00 AM EDT - 1 year ago

CalciMedica Presents Data from Preclinical Studies of Auxora in Acute Kidney Injury at the 29th International AKI & CRRT Conference

CalciMedica Announces Presentation of Data from a Preclinical Study of Auxora in Acute Kidney Injury at the 29th International AKI & CRRT Conference

Feb 28, 2024, 6:57 PM EST - 1 year ago

CalciMedica Announces Presentation of Data from a Preclinical Study of Auxora in Acute Kidney Injury at the 29th International AKI & CRRT Conference

CalciMedica Announces FDA Clearance of IND Application for Phase 2 Trial of Auxora™ for the Treatment of Severe Acute Kidney Injury

Feb 13, 2024, 8:00 AM EST - 1 year ago

CalciMedica Announces FDA Clearance of IND Application for Phase 2 Trial of Auxora™ for the Treatment of Severe Acute Kidney Injury

CalciMedica to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference

Feb 7, 2024, 4:05 PM EST - 1 year ago

CalciMedica to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference

CalciMedica Announces Private Placement of up to Approximately $55 Million

Jan 22, 2024, 8:00 AM EST - 1 year ago

CalciMedica Announces Private Placement of up to Approximately $55 Million

CalciMedica Reports Third Quarter 2023 Financial Results and Provides Clinical & Corporate Updates

Nov 9, 2023, 7:00 AM EST - 2 years ago

CalciMedica Reports Third Quarter 2023 Financial Results and Provides Clinical & Corporate Updates

CalciMedica Announces Presentation of Initial Data from the CRSPA Study of Auxora at the 65th Annual ASH Meeting & Exposition

Nov 2, 2023, 9:15 AM EDT - 2 years ago

CalciMedica Announces Presentation of Initial Data from the CRSPA Study of Auxora at the 65th Annual ASH Meeting & Exposition

CalciMedica Announces Upcoming Presentations and Events in September

Sep 6, 2023, 7:30 AM EDT - 2 years ago

CalciMedica Announces Upcoming Presentations and Events in September

CalciMedica to Host Acute Pancreatitis Clinical Experts Event on September 21, 2023

Aug 31, 2023, 7:30 AM EDT - 2 years ago

CalciMedica to Host Acute Pancreatitis Clinical Experts Event on September 21, 2023

CalciMedica Announces First Patient Enrolled in International Expansion of CARPO Trial of Auxora™ in Acute Pancreatitis (AP)

Aug 9, 2023, 7:30 AM EDT - 2 years ago

CalciMedica Announces First Patient Enrolled in International Expansion of CARPO Trial of Auxora™ in Acute Pancreatitis (AP)

CalciMedica Announces Relisting on Nasdaq

Jun 12, 2023, 7:30 AM EDT - 2 years ago

CalciMedica Announces Relisting on Nasdaq

CalciMedica Announces Publication of Preclinical Data in Journal of Clinical Investigation (JCI) Insight Supporting the Development of CRAC Channel Inhibitors for Chronic Pancreatitis (CP)

Jun 6, 2023, 7:30 AM EDT - 2 years ago

CalciMedica Announces Publication of Preclinical Data in Journal of Clinical Investigation (JCI) Insight Supporting the Development of CRAC Channel Inhibitors for Chronic Pancreatitis (CP)

Life Biosciences Expands Team with the Appointment of Ming Yang, Ph.D., as SVP of Research and Development

May 23, 2023, 8:00 AM EDT - 2 years ago

Life Biosciences Expands Team with the Appointment of Ming Yang, Ph.D., as SVP of Research and Development

MrAlientrader
MrAlientrader Nov. 14 at 9:03 PM
$CALC down 7% with only 7k shares traded :)
0 · Reply
MrAlientrader
MrAlientrader Nov. 14 at 4:01 PM
$CALC seems no one is selling except thise price manipulator’s fake trading
0 · Reply
d_risk
d_risk Nov. 12 at 10:23 PM
$CALC - CalciMedica, Inc. - 10Q - Updated Risk Factors CALC’s 10-Q risk factors now focus on expanded clinical trial, regulatory, and commercialization hurdles for Auxora, new IP and trademark disputes, detailed compliance and international trade risks, stock volatility, and the impact of future share sales—while streamlining prior disclosures and removing some economic and delisting risks. #Pharmaceuticals #StockVolatility #IntellectualProperty #RegulatoryRisk #ClinicalTrials 🟢 Added 🟠 Removed https://d-risk.ai/CALC/10-Q/2025-11-12
0 · Reply
PresumingEd
PresumingEd Nov. 10 at 12:17 PM
$CALC https://uk.marketscreener.com/news/calcimedica-presents-data-from-preclinical-study-of-auxoraa-in-an-animal-model-of-aki-at-asn-kidne-ce7d5fd8d88dff26
0 · Reply
clueful
clueful Nov. 6 at 1:01 PM
$CALC once this flies and actually gets found by people, it can only go up. And a lot.
0 · Reply
MrAlientrader
MrAlientrader Nov. 5 at 9:02 PM
$CALC started accumulating again below $3, thank you shorts for another opportunity, please drive it lower
0 · Reply
AmySharp603
AmySharp603 Oct. 29 at 4:50 PM
$CALC creating smarter solutions; AITX creating safer streets — AI-powered RADCam Enterprise now helping Taylor Police deter crime in real time. 🚓
0 · Reply
Regzw
Regzw Oct. 27 at 8:37 PM
$BYND everybody check out $CALC most insider buying I ever saw!!!
3 · Reply
Regzw
Regzw Oct. 27 at 8:37 PM
$GME everybody check out $CALC most insider buying I ever saw!!!!
0 · Reply
Regzw
Regzw Oct. 27 at 8:35 PM
$BB everybody check out $CALC most insider buying I ever saw!!!!!
0 · Reply
Regzw
Regzw Oct. 27 at 8:34 PM
$TRUMP.X check out $CALC most insider buying I ever saw!!!
0 · Reply
Regzw
Regzw Oct. 27 at 8:32 PM
$TARA check out $CALC most insider buying I ever saw!!!!
0 · Reply
Regzw
Regzw Oct. 27 at 8:32 PM
$CLIK check out $CALC most insider buying I ever saw!!!
0 · Reply
Regzw
Regzw Oct. 27 at 8:31 PM
$RR $CALC check out calc most insider buying I ever saw!!!!
0 · Reply
pablo4
pablo4 Oct. 16 at 5:34 PM
$CALC tick tock....when does the bomb go off here?
0 · Reply
MrAlientrader
MrAlientrader Oct. 14 at 8:06 PM
$CALC the price manipulation back again mean big upside is coming in the near future. They always come to manipulate the price down and the accumulate the most before big pop
0 · Reply
pablo4
pablo4 Oct. 13 at 5:22 PM
$CALC somebody keeps trying to pin this one in place.....but some major news is getting closer and closer....the coming phase 2 update on the AKI trial is very significant IMO. Yes, it's still a few months away but starting to get close enough for speculation to drive this seller out of Dodge, IMO.
0 · Reply
InfinityVenom
InfinityVenom Oct. 10 at 7:45 PM
$CALC bullshit as usual. thanks trump for tweating and fucking it up. we had a good breakout going
0 · Reply
pablo4
pablo4 Oct. 10 at 3:36 PM
$CALC is trying to buck the trend.....Trump has responded to China's monopolistic moves on withholding raw earth materials by threatening massive new tariffs. The market is deep red now after opening strong again. CALC is behind on getting its due relative to some other bios in the recent biotech bull run. Let's see how it does in all this.
0 · Reply
kshonstocks
kshonstocks Oct. 10 at 2:20 PM
$CALC on scans, trying for the higher highs
0 · Reply
pablo4
pablo4 Oct. 10 at 2:05 PM
$CALC one more.....could it fall back again? Yes, anything's possible in the stock market. But, don't say someone didn't offer an opinion that one might be close to missing the boat here and now. JMO.
0 · Reply
pablo4
pablo4 Oct. 10 at 1:50 PM
$CALC I believe shares are drying up at this low to mid 3s level and we will move solidly into the 4s or 5s very soon. Of course, that's just opinion. But with a strong biotech market tailwind (finally) and major CALC catalysts nearing by the day....not to mention all the aggressive insider buying....this thing is on the launching pad, IMO.
0 · Reply